| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968389 | Vaccine | 2012 | 6 Pages |
Abstract
⺠Mismatch between vaccine and circulating strains impairs vaccine immunogenicity. ⺠Intradermal route (ID) of administration has been shown to enhance immunogenicity. ⺠Intanza® 15 μg is the first licensed ID inactivated split-virion influenza vaccine. ⺠We evaluated its ability to elicit antibody response against H3N2 circulating viruses. ⺠Intanza® 15 μg elicited broader antibody responses than IM vaccine in the elderly.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Filippo Ansaldi, Paola Canepa, Antonella Ceravolo, Laura Valle, Daniela de Florentiis, Raymond Oomen, Frederick R. Vogel, Martine Denis, Sandrine I. Samson, Giancarlo Icardi,